G9036 HCPCS Level II code: Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
CMS terminated G9036: its last date of service was Dec 31, 2019. It stays here for looking up older claims; newer services need a current code.
Official description
G9036Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
Short description: Rimantadine hcl, brand
HCPCS · United States
Medicare details
The indicators CMS publishes with G9036 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Other drugs
- Added
- Dec 1, 2004
- Terminated after
- Dec 31, 2019
Where G9036 sits
- 1G codesProcedures and professional services
- 2Terminated G9036Rimantadine hydrochloride, oral, brand, per 100 mg (for use in a medicare-approved demonstration project)
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code G9036 still valid?
No. CMS terminated G9036; its last date of service was Dec 31, 2019. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover G9036?
CMS lists G9036’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9036
All G codesG9018Zanamivir, inhalation powder, administered through inhaler, per 10 mg (for use in a medicare-approved demonstration project)G9019Oseltamivir phosphate, oral, per 75 mg (for use in a medicare-approved demonstration project)G9020Rimantadine hydrochloride, oral, per 100 mg (for use in a medicare-approved demonstration project)G9033Amantadine hydrochloride, oral brand, per 100 mg (for use in a medicare-approved demonstration project)G9034Zanamivir, inhalation powder, administered through inhaler, brand, per 10 mg (for use in a medicare-approved demonstration project)G9035Oseltamivir phosphate, oral, brand, per 75 mg (for use in a medicare-approved demonstration project)G9037Interprofessional telephone/internet/electronic health record clinical question/request for specialty recommendations by a treating/requesting physician or other qualified health…G9038Co-management services with the following elements: new diagnosis or acute exacerbation and stabilization of existing condition; condition which may benefit from joint care…G9050Oncology; primary focus of visit; work-up, evaluation, or staging at the time of cancer diagnosis or recurrence (for use in a medicare-approved demonstration project)G9051Oncology; primary focus of visit; treatment decision-making after disease is staged or restaged, discussion of treatment options, supervising/coordinating active cancer directed…G9052Oncology; primary focus of visit; surveillance for disease recurrence for patient who has completed definitive cancer-directed therapy and currently lacks evidence of recurrent…G9053Oncology; primary focus of visit; expectant management of patient with evidence of cancer for whom no cancer directed therapy is being administered or arranged at present; cancer…